G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer [RNA-seq]
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Ovarian cancerThis series is part of our curated briefing on it.
- Samples
- 24 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cellsGenome biology · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE279501_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1173150 and SRA study SRP538663. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 8 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8573506 PEO1 A, RNA, Rep1 PEO1 A, RNA,
- GSM8573507 PEO1 A, RNA, Rep 2 PEO1 A, RNA,
- GSM8573508 PEO1 A, RNA, Rep3 PEO1 A, RNA,
- GSM8573509 PEO4 A, RNA, Rep1 PEO4 A, RNA,
- GSM8573510 PEO4 A, RNA, Rep2 PEO4 A, RNA,
- GSM8573511 PEO4 A, RNA, Rep3 PEO4 A, RNA,
- GSM8573512 PEO1 B, PDS 2hr, RNA, Rep1 PEO1 B, PDS 2hr, RNA,
- GSM8573513 PEO1 B, PDS 2hr, RNA, Rep2 PEO1 B, PDS 2hr, RNA,
- GSM8573514 PEO1 B, PDS 2hr, RNA, Rep3 PEO1 B, PDS 2hr, RNA,
- GSM8573515 PEO1 B, PDS 6hr, RNA, Rep1 PEO1 B, PDS 6hr, RNA,
- GSM8573516 PEO1 B, PDS 6hr, RNA, Rep2 PEO1 B, PDS 6hr, RNA,
- GSM8573517 PEO1 B, PDS 6hr, RNA, Rep3 PEO1 B, PDS 6hr, RNA,
- GSM8573518 PEO4 B, PDS 2hr, RNA, Rep1 PEO4 B, PDS 2hr, RNA,
- GSM8573519 PEO4 B, PDS 2hr, RNA, Rep2 PEO4 B, PDS 2hr, RNA,
- GSM8573520 PEO4 B, PDS 2hr, RNA, Rep3 PEO4 B, PDS 2hr, RNA,
- GSM8573521 PEO4 B, PDS 6hr, RNA, Rep1 PEO4 B, PDS 6hr, RNA,
- GSM8573522 PEO4 B, PDS 6hr, RNA, Rep2 PEO4 B, PDS 6hr, RNA,
- GSM8573523 PEO4 B, PDS 6hr, RNA, Rep3 PEO4 B, PDS 6hr, RNA,
- GSM8573524 PEO1 B, RNA, Rep1 PEO1 B, RNA,
- GSM8573525 PEO1 B, RNA, Rep2 PEO1 B, RNA,
- GSM8573526 PEO1 B, RNA, Rep3 PEO1 B, RNA,
- GSM8573527 PEO4 B, RNA, Rep1 PEO4 B, RNA,
- GSM8573528 PEO4 B, RNA, Rep2 PEO4 B, RNA,
- GSM8573529 PEO4 B, RNA, Rep3 PEO4 B, RNA,
- GSE135242 Hi-C identifies structural variation associated with resistance in paired patient-derived ovarian cancer models 8 samples same disease briefing · shares resistance, ovarian
- GSE268514 Integrative genomic analysis of Korean high-grade serous ovarian cancer 161 samples same disease briefing · shares ovarian
- GSE311212 Transcriptomic profiling in human ovarian cancer cell line OVCAR-3 following CDK2 inhibitor treatment 6 samples same disease briefing · shares ovarian
- GSE154600 Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma 5 samples same disease briefing · shares ovarian
- GSE128098 TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target 4 samples same disease briefing · shares ovarian
- GSE57477 Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes 72 samples same disease briefing · shares ovarian
- GSE314300 Rb CUT&RUN profiling in ovarian cancer cell lines following CDK2 inhibitor treatment 10 samples same disease briefing · shares ovarian
- GSE28330 Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents 107 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.